Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X about a recent paper by him and colleagues published in Journal of Clinical Oncology:

“Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?

Academia has the ethical duty to explore de-escalation strategies to maintain efficacy and reduce toxicity and cost.

In the Journal of Clinical Oncology, a fascinating review led by Jordi Remon, Benjamin Besse, Lizza Hendriks, Martina Bortolot and coauthors.

Happy to contribute to this global call for action.”

“De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?”

Authors: Jordi Remon, Benjamin Besse, Giannis Mountzios, Lizza Hendriks, Martina Bortolot et al.

Giannis Mountzios: Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?

More posts featuring Giannis Mountzios.